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Background: Pre-exposure prophylaxis (PrEP) with daily Truvada [a combination of emtricitabine (FTC) and
tenofovir disoproxil fumarate (TDF)] is a novel HIV prevention strategy recently found to prevent HIV transmission
among men who have sex with men and heterosexual couples. Acute infection in adherent persons who fail PrEP
will inevitably occur under concurrent antiretroviral therapy, thus raising questions regarding the potential impact of
PrEP on early viral dynamics. We investigated viral evolution dynamics in a macaque model of PrEP consisting of
repeated rectal exposures to SHIV162P3 in the presence of PrEP.
Results: Four macaques were infected during daily or intermittent PrEP with FTC or FTC/TDF, and five were untreated
controls. SHIV env sequence evolution was monitored by single genome amplification with phylogenetic and sequence
analysis. Mean nucleotide divergence from transmitted founder viruses calculated 17 weeks (range=12–20) post peak
viremia was significantly lower in PrEP failures than in control animals (7.2 × 10-3 compared to 1.6 × 10-2 nucleotide
substitutions per site per year, respectively, p< 0.0001). Mean virus diversity was also lower in PrEP failures after 17 weeks
(0.13% vs. 0.53% in controls, p< 0.0001).
Conclusions: Our results in a macaque model of acute HIV infection suggest that infection during PrEP limits early virus
evolution likely because of a direct antiviral effect of PrEP and/or reduced target cell availability. Reduced virus
diversification during early infection might enhance immune control by slowing the selection of escape mutants.
Keywords: Single genome amplification, Pre-exposure prophylaxis, Emtricitabine, TruvadaBackground
Oral administration of antiretroviral (ARV) drugs before ex-
posure to HIV (pre-exposure prophylaxis [PrEP]) is a novel
prevention strategy to protect high-risk HIV-1-negative
people from becoming infected [1]. Two recently completed
trials with daily Truvada (a combination of emtricitabine
[FTC] and tenofovir disoproxil fumarate [TDF]) have pro-
vided the first indication that oral PrEP reduces HIV trans-
mission [2,3]. In these trials, the incidence of HIV-1 was
reduced by 44% among men who have sex with men
(MSM) and 62.6% among heterosexual couples; efficacy
was substantially higher for study participants who reported
high adherence or were on study medication [2,3]. An add-
itional clinical trial among serodiscordant couples recently
discontinued the placebo arm due to the strong HIV pre-
vention effect seen by TDF (62% fewer infections) and* Correspondence: GGarcia-Lerma@cdc.gov
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reproduction in any medium, provided the orTruvada (73% fewer infections) [4]. A fourth trial (FEM-
PrEP) with Truvada among high-risk women was recently
stopped due to futility as a result of low adherence.
Since current PrEP regimens are not 100% protective, it
is essential to understand the characteristics of acute infec-
tions that occur during PrEP use in humans. In contrast to
natural HIV infections that are characterized by the ab-
sence of selective pressures prior to the development of
acquired immune responses, early replication and systemic
dissemination during infections that occur during PrEP
can face an increased genetic bottleneck due to ARV drug
activity. Strong drug selective pressures have the potential
to shape early virus evolution and diversification from
transmitted/founder viruses and alter host immune
responses. Infection of non-human primates with SHIV
can be used to model how PrEP influences early viral and
immunological parameters. This model can recapitulate
human infection by using R5-tropic isolates and low
challenge doses that better mimic the transmission dy-
namics of HIV infection [5]. We recently found thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment with FTC or Truvada had lower peak viremias
and a more rapid decline of virus loads to set-point levels
compared to untreated animals, likely due to continued
antiretroviral drug treatment during acute infection [6-8].
Interestingly, macaques infected during PrEP had altered
acute immune parameters including delayed maturation of
antibody avidity against multiple structural and functional
antigens, reduced inflammatory responses, and minimal
early CD4+ T cell losses [6-10]. While these unique
immune parameters likely reflected reduced virus replica-
tion under PrEP, they also raised questions about the
dynamics of the virus population during acute infection.
The study of early HIV and SIV sequences by single-
genome amplification (SGA) provides an accurate picture
of the characteristics of transmitted/founder HIV and
SIV variants and the distribution of viral quasispecies
during primary infection [11,12]. In the absence of adap-
tive immune pressure or other selective pressures, virus
diversification shortly after infection follows a pattern of
random evolution with an almost star like phylogeny and
a Poisson distribution of nucleotide substitutions [13].
Here we use SGA and sequence analysis to assess the
impact of antiretroviral drugs during PrEP failure on viral
dynamics. We demonstrate that PrEP confers a severe
bottleneck that significantly slows early virus evolution
and diversification. These findings in macaques highlight
the need to better understand the impact of PrEP on
acute HIV infection and the natural course of disease in
humans.
Results
Dynamics of acute viral infection in treated and untreated
macaques
Figure 1 shows the kinetics of virus replication and
seroconversion in the nine treated and untreated SHIV-
infected macaques. Peak viremias in untreated control
macaques AG94, AI22, AO86, AM20, and 17 V were
7.3, 7.8, 7.7, 7.6, and 8.2 log10 RNA copies/ml, respect-
ively. Peak viremias in the two daily FTC (4.3 and 5.6
log10 copies/ml) and the two intermittent Truvada fail-
ures (5.8 and 6.1 log10 copies/ml) were lower, consistent
with the generally blunted acute viremias seen in maca-
ques infected during PrEP in previous studies [6-8]
(Figure 1). Macaques AG80 and AG46 received daily
FTC for 29 and 24 weeks after the first detectable SHIV
RNA in plasma, respectively; AG46 developed the
M184V mutation associated with FTC resistance
11 weeks after infection (Figure 1; red dots). The fre-
quency of M184V-containing mutants determined by
sensitive real-time PCR was low (16-20%) at week 11,
below the assay cutoff (0.6%) at week 12, and high
(100%) 22 weeks after infection (not shown) [8]. Maca-
ques DK40 and DL6V also continued receiving twoweekly doses of Truvada for 19 and 14 weeks after in-
fection, respectively (Figure 1). Neither of these two
macaques had detectable mutations associated with FTC
(M184V) or tenofovir (TFV) (K65R) resistance (not
shown), despite the long intracellular half-life of FTC-
triphosphate and TFV-diphosphate [7,8]. All animals
seroconverted within 2–5 weeks after the first detection
of RNA in plasma (Figure 1).
Viral diversity in the SHIV162P3 virus stock and in control
untreated SHIV162P3 infections
Twenty-three env nucleotide sequences were generated
by SGA for the SHIV162P3 stock. Consistent with the lim-
ited heterogeneity of the SHIV162P3 virus stock [14,15],
the overall nucleotide diversity was found to be low
(mean = 0.09%; min, max = 0–0.5%) (Figure 2).
We generated 326 env sequences from plasma by SGA
in the five untreated control macaques infected rectally
with SHIV162P3. The specific time points used for SGA
analysis are denoted as green dots in Figure 1 and are
referred as weeks after peak viremia. Of the 326 env
sequences, 88 were obtained from macaque AI22 (30 at
peak viremia, 24 after 16 weeks, and 34 after 24 weeks),
72 from macaque AG94 (23 at peak viremia, 21 after
19 weeks, and 28 after 26 weeks), 48 from macaque
AO86 (28 at peak viremia and 20 after 20 weeks), 37
from macaque AM20 (20 at peak viremia and 17 after
18 weeks), and 81 from macaque 17 V (27 at peak
viremia, 31 at week 12, and 25 at week 25). Figure 3
shows the neighbor-joining tree and Highlighter plots
generated with env sequences from these macaques and
demonstrate that all 5 animals were infected by a single
variant as indicated by the limited number of env
sequences seen at peak viremia [16].
We next calculated the genetic diversity of env sequences
obtained from longitudinal plasma specimens collected at
several time points after infection. Mean env diversity in
control macaque AI22 at peak viremia was 0.02% (min,
max=0–0.3) and increased to 0.72% after 16 (min, max=
0–1.6) and 24 weeks (min, max =0-1.7). Similarly, mean
env diversity in control macaque AG94 was 0.1% (min,
max=0–0.40) at peak viremia, 0.92% (min, max=0.1-1.9)
after 19 weeks, and 0.96% (min, max=0–1.9) after
26 weeks. For macaques AO86, AM20, and 17 V, mean env
diversity at peak viremia was 0.07% (min, max=0, 0.4),
0.04% (min, max=0, 0.3) and 0.04% (min, max=0, 0.3),
respectively. Diversity increased in macaques AM20
(mean=0.43%; min, max=0–1.0) and 17 V (mean=0.47;
min, max=0, 1.1) after 18 and 12 weeks, respectively, and
remained low in macaque A086 after 20 weeks (mean=
0,08; min, max=0–0.3). Figure 4 shows the increasing env
nucleotide divergence from transmitted founder viruses
seen in 4 of the 5 control macaques over time. Mean nu-

































































































































































































































Figure 1 Viral kinetics and serologic responses in acute SHIV162P3 infections. Macaques AM20, AO86, 17 V, AG94, and AI22 are untreated
controls. Macaques AG80, AG46, DK40, and DL6V were infected during concurrent PrEP. All 9 macaques were exposed rectally once a week until
the first evidence of SHIV RNA in plasma. Red asterisks indicate seroconversion and green circles indicate time points that were analyzed by SGA.
The 4 red dots in macaque AG46 represent time points with detectable M184V mutation (8). Horizontal lines denote the period of time under
ARV drug exposure.
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3.0 ×10-2 in AG94.
Limited viral diversity in SHIV162P3-infected macaques
failing daily or intermittent PrEP with FTC or Truvada
We next explored the degree of viral diversity in the four
macaques infected with SHIV162P3 during daily or inter-
mittent PrEP. Figure 5 shows the neighbor-joining tree
and Highlighter plots in these four PrEP breakthrough ani-
mals showing the limited viral env diversity in these ani-
mals. Mean env nucleotide diversity in macaques AG80
and AG46 that failed daily FTC was low both at peak
viremia and after 16 to 18 weeks of follow up. In these two
animals, the overall env diversity at peak viremia was
0.015% (min, max=0, 0.2) and 0.025% (min, max= 0, 0.2),
respectively. Virus diversity remained low in AG80 at week
18 (mean=0.12; min, max=0, 0.6) and in AG46 at week
16 (mean=0.26; min, max=0, 0.6) (Figure 5).Low diversity was also seen in macaques DL6V and
DK40 that failed intermittent PrEP with two weekly doses
of Truvada. Diversity of env sequences at peak viremia was
0.05% (min, max=0, 0.2) and 0.025% (min, max= 0, 0.2)
for macaques DL6V and DK40, respectively, and remained
low at week 15 in DL6V (mean= 0.12; min, max=0, 0.5),
and at weeks 18 and 26 in DK40 (mean=0.04 (min, max=
0, 0.3) and 0.11 (min, max= 0, 0.5), respectively).
We also evaluated env nucleotide divergence from the
transmitted founder viruses after 17 weeks in all 4 animals
infected during PrEP (Figure 4). Mean nucleotide substitu-
tions per site per year were 6.2×10-3 (min, max=5.8×10-3,
8.7 ×10-3) for AG80, 7.6 ×10-3 (min, max=3.2×10-3,
9.8 ×10-3) for AG46, 5.9 ×10-3 (min, max=0, 1.2 ×10-2) for
DK40, and 9.7×10-3 (min, max=3.5×10-3, 1.8×10-2) for
DL6V.
The degree of env diversity and nucleotide divergence
from the transmitted founder was compared between PrEP
Figure 2 Highlighter plot of env sequences generated from the
SHIV162P3 challenge stock by single genome amplification.
Nucleotide changes are colored as follows: A, green; T, red; G,
orange; C, light blue. Gaps are indicated in gray. Circles denote
APOBEC-mediated G-to-A hyper mutation. Diamonds represent G-to-
A conversions.
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for a similar follow up time, this analysis was limited to the
first 17 weeks of infection (range= 12–20 for controls and
15–18 for PrEP breakthroughs), and excluded the late time
points that were only available in a few animals (24 weeks
for AI22, and 26 weeks for AG94, 17 V, and DK40). Over
this 17 week period of time, the overall nucleotide diver-
gence from transmitted founder viruses in the 4 PrEP
breakthrough animals (7.2× 10-3; min, max=5.9 × 10–3,
9.7× 10-3) was significantly lower than in the five untreated
control animals (1.6× 10-2; min, max= 3.7× 10-3, 3.0 × 10-2,
p< 0.0001) (Figure 4). Table 1 shows that the overall env
diversity in the 4 PrEP breakthrough infections was also
significantly lower than that seen in the 5 untreated
control macaques both at peak viremia and after 17 weeks
of infection. The Neighbor-joining phylogenetic analysis of
all 9 macaques and the SHIV162P3 virus stock env
sequences are shown in Figure 6 and illustrate how PrEP
blunts the initial generation of virus diversity and diversifi-
cation relative to untreated control animals.
Amino acid mutations in variable regions of Env gp120
To evaluate the effect of the observed nucleotide substitu-
tions on Env protein evolution, we examined amino acidchanges in the V1-V5 regions of consensus env sequences
from all 9 macaques. No changes were observed in V1-V4
Env sequences from the four PrEP breakthroughs animals
during the 15–26 weeks of follow up (Figure 7). Macaque
DK40 had a single V451K change in V5, and macaque
AG46 had a novel potential N-linked glycosylation site at
position 453 of V5 (Figure 7). In contrast, 4 of the 5 un-
treated control macaques acquired multiple amino acid
changes overtime in V1, V2, V3, or V5. At weeks 19 and 26
after peak viremia, untreated macaque AG94 acquired a
novel potential N-linked glycosylation site at position 129
(H129N) in V1, N148D and D184N changes in V2, a
P296H change in V3, and an R420K change in V5. Simi-
larly, untreated macaque AI22 acquired the P296H change
in V3 and the R420K/E change in V5 over time; macaque
AO86 acquired an E421K change in V5, and macaque 17 V
acquired N132D in V1, P296H in V3, and E421N in V5
(Figure 7). The Geno2pheno algorithm did not predict a
change in co-receptor tropism associated with P296H in
V3. Control macaque AM20 did not acquire any amino
acid changes in V1-V5 during this period of time
(Figure 7).
Discussion
We used a macaque model of rectal SHIV transmission to
explore the impact of PrEP on early virus evolution. Previ-
ously, we had found that SHIV infection of macaques dur-
ing concurrent PrEP was characterized by 100- to 1000-
fold lower peak viremias and a more rapid virus decline
compared to untreated macaques [6-8]. It is unlikely that
these low peak viremias are due to specific MHC-I geno-
types since MHC-I alleles do not affect virus loads within
the first few weeks of infection [17]. While MHC-I alleles
and immune parameters can plausibly affect chronic phase
viremias, the blunted acute viremias seen in our PrEP
breakthrough animals likely reflect continuous ARV drug
activity since PrEP regimens were maintained for 15 to
20 weeks after infection. Here, we demonstrate that such
reduced acute viremias are associated with limited virus di-
versity and little or no env diversification during the first 20
to 30 weeks of infection. In contrast to viruses from 4 out
of 5 untreated macaques that acquired multiple env muta-
tions in V1-V5, we only found two amino acid changes in
the V5 region from 2 of the 4 PrEP failures. ARV treatment
during acute infection may substantially limit replication
and/or select for variants with reduced RT function relative
to wild type. These virological findings are consistent with
earlier immunological studies in macaques that noted
delayed maturation of antibody avidity and reduced inflam-
matory responses and early CD4+ T cell loss associated
with PrEP use or acute ARV treatment [6-10,18,19].
Our finding of limited viral evolution in the PrEP break-
through animals may have important public health impli-
































































Figure 3 Neighbor-joining tree and highlighter analysis of env sequences generated by single genome amplification in untreated
control macaques AI22, AO86, AG94, AM20, and 17 V. Nucleotide changes are colored as follows: A, green; T, red; G, orange; C, light blue.
Gaps are indicated in gray. Circles denote APOBEC-mediated G-to-A hyper mutation. Diamonds represent G-to-A conversions.










































































































Figure 4 Viral divergence from the transmitted founder (T/F) env sequence in SHIV162P3-infected untreated controls (AM20, AO86, 17 V,
AG94, and AI22) and PrEP-treated macaques (AG80, AG46, DK40, and DL6V). V1-V5 env sequences were amplified by single genome
amplification from longitudinal plasma specimens collected 15 to 26 weeks after peak viremia. For the analysis of divergence, nucleotide
sequences were aligned and the means and standard deviations for all pair-wise comparisons between individual sequences and the T/F were
calculated using the maximum composite likelihood in MEGA5.
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[20]. For instance, HIV-specific CD8+ T cell responses
during primary infection are critical determinants for the
subsequent control of viremia [21]. In HIV and SIV infec-
tions, the relatively homogeneous virus population seen at
peak viremia subsequently undergoes significant evolution
that rapidly increases the capacity to adapt to host im-
mune responses [20]. A limited evolutionary potential
associated with PrEP use may diminish the ability of HIV
to escape host immune responses and enhance initial virus
control. Limited virus evolution might also increase the
window of vulnerability of HIV to vaccine-elicited immune
responses as recently noted in vaccinated macaques receiv-
ing a sub-optimal dose of a topical microbicide [22].
The analysis of early env sequences from the five un-
treated macaques suggested that infection of these ani-
mals was initiated by a single founder virus, a finding
that is consistent with the generally low multiplicity of
infection associated with rectal infections in macaquesand humans [5,14,23]. This observation is also consistent
with the low (10 TCID50) virus inoculum used to infect
these animals and the limited heterogeneity of the
SHIV162P3 virus stock [14,15]. A similar analysis sug-
gested that infection in our animals receiving PrEP was
also initiated by a single variant. However, estimation of
the number of transmitted/founder variants in these
PrEP breakthrough animals is difficult since continuous
ARV drug activity might potentially favor monospecific
expansions of viruses with fitness advantages in the pres-
ence of ARVs. Selection of these viruses would likely
shape the virus population in the animals.
The alterations in early viral and immunological para-
meters seen in this and earlier studies are noteworthy and
deserve careful consideration. Blunted acute viremias might
conceivably reduce gut CD4 Tcell depletion, favor early res-
toration of mucosal T cells in the gut, and attenuate the
course of infection [24]. However, our macaque model is
















































Figure 5 Neighbor-joining and highlighter analysis of env sequences generated by single genome amplification in PrEP breakthrough
infections. Animals AG80 and AG46 were infected during daily PrEP with FTC, and animals DK40 and DL6V were infected during intermittent
PrEP with Truvada. Nucleotide changes are colored as follows: A, green; T, red; G, orange; C, light blue. Gaps are indicated in gray. Circles denote
APOBEC-mediated G-to-A hyper mutation. Diamonds represent G-to-A conversions.
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SHIV162P3 infections are characterized by early acute vire-
mias similar to those seen in humans, but also low virus set
points that generally result in a non-pathogenic disease
course [25]. Unfortunately, the low set point viremias also
preclude a more comprehensive analysis of viral evolution
after PrEP discontinuation.Table 1 SHIV162P3 env diversity in PrEP breakthroughs
and untreated control macaques
Mean nucleotide diversity (%) (range)
PrEP Controls P value
Peak 0.027 (0.015-0.05) 0.053 (0.02-0.10) P< 0.0001
Week 17* 0.14 (0.04-0.26) 0.53 (0.08-0.92) P< 0.0001
* Sequences were obtained an average of 17 weeks post peak viremia for the
4 PrEP breakthroughs (15, 16, 18, and 18 weeks) and the 5 untreated controls
(12, 16, 18, 19, and 20 weeks).In summary, we show in macaques that drug selective
pressures associated with ARV use for PrEP significantly limit
early virus replication and evolution, reinforcing the need to
evaluate these parameters in humans. The impact of PrEP on
early infection in humans is not known and will likely depend
on both the extent of ARV drug exposure at the time of in-
fection and prior to HIV diagnoses. This interval will typically
be several weeks and might be sufficient to affect early virus
evolution and immune responses. Careful analysis of the
characteristics of HIV infections in highly adherent partici-
pants from ongoing clinical trials may help to clarify how
PrEP use may impact early infection, risks for secondary
transmission, and the rate of progression to HIV disease.
Conclusions
We explored in macaques the impact of PrEP on early viral























Figure 6 Phylogenetic analysis of SHIV162P3 challenge stock and longitudinal env sequences generated by single genome amplification
in all six infected macaques. The neighbor-joining method was used for the analysis. V1-V5 env sequences from individual macaques are color coded. PrEP
breakthrough infections are characterized by a reduced generation of virus diversity relative to untreated animals as evidenced by the length of the branches.
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taining the initial explosion of virus replication and diversifi-
cation. These virological findings complement earlier
immunological studies in macaques that noted altered im-
mune responses associated with PrEP. Our findings
emphasize the need to understand the characteristics of
HIV infections that occur during PrEP implementation in
humans.
Methods
Macaques and experimental SHIV infection
A total of nine male Indian rhesus macaques infected
rectally with SHIV162P3 were studied. SHIV162P3 is a chimeric
virus that contains the tat, rev, and env coding regions ofHIV-1SF162 in a SIVmac239 background (National Insti-
tutes of Health AIDS Research and Reference Reagent Pro-
gram [26]). All animals became infected during repeated
weekly non-traumatic exposures to a low dose (10 TCID50)
of SHIV162P3 as previously described [7,8]. Macaques AG80
and AG46 received daily PrEP with human-equivalent doses
of FTC (20 mg/kg) and became infected after 5 and 10 rectal
exposures, respectively. Macaques DK40 and DL6V received
intermittent PrEP with 2 weekly human-equivalent doses of
Truvada (22 mg/kg TDF and 20 mg/kg FTC) and became
infected after 2 and 4 rectal challenges, respectively (6, 7).
Macaques AM20, 17 V, AO86, AI22, and AG94 are un-
treated control animals that did not receive PrEP and be-
came infected after 3, 1, 1, 5 and 3 rectal exposures,
162p3     VTLHCTNLEN ATNTTSSNWK EMNRGEIKNC SFNVTTSIGN KMQKEYALFY KLDVVPIDND NTSYNLINCN TSVITQACPK VSFEPIPIHY CAPAGFAILK CNDKKFNGSG PCINVSTVQC
AI22 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AI22 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AI22 24wk .......... .......D.. .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG94 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG94 19wk ...N...... .......... ..D....... .......... .......... .......N.. .......... .......... .......... .......... .......... .......... 
AG94 26wk ...N...... .......... ..D....... .......... .......... .......N.. .......... .......... .......... .......... .......... .......... 
A086 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
A086 20wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AM20 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AM20 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
17V  peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
17V  12wk ...... D... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
17V  26wk ...... D.G. .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ......S... 
DK40 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DK40 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DK40 26wk .......... .......... .......... .......... .......... .......... .......... ..... ..... .......... .......... .......... .......... 
AG46 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG46 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG80 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG80 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DL6V peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DL6V 15wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
162p3     VFKQSSGGDP EIVMHSFNCG GEFFYCNSTQ LFNSTWNNTI GPNNTNGTIT LPCRIKQIIN RWQEVGKAMY APPIRGQIRC SSNITGLLLT RDGGREVSNT TEIFRPG 
AI22 peak .......... .......... .......... ....A..... .......... .......... .......... .......... .......... .......... ....... 
AI22 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... ....K..... ....... 
AI22 24wk .......... .......... .......... .......... .......... .......... .......... .......... .......... ....E..... ....... 
AG94 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
AG94 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... ....K..... .......
AG94 24wk .......... .......... .......... .......... .......... .......... .......... .......... .......... ....K..... .......
A086 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
A086 20wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .....K.... ....... 
AM20 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
AM20 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
17V  peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
17V  12wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
17V  26wk ..E....... .......... .........P .......... ?......... .......... .......... .......... .......... ..... N.... ....... 
DK40 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
DK40 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .....K.... ....... 
DK40 26wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .....K...A ....... 
AG46 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......
AG46 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......N.. ....... 
AG80 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
AG80 18wk .......... .V........ .......... .......... .......... .......... .......... .......... .......... ...D...... ....... 
DL6V peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
DL6V 15wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ....... 
162p3     PCINVSTVQC THGIRPVVST QLLLNGSLAE EGVVIRSENF TDNVKTIIVQ LKESVEINCT RPNNNTRKSI PIGPGKAFYA TGDIIGDIRQ AHCNISGEKW NNTLKQIVTK LQAQFENKTI
AI22 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AI22 16wk .......... .......... .......... .E........ .......... .......... .......... .......... .......... .......... S......... .......... 
AI22 24wk .......... .......... .......... .E........ .......... .......... .......... H......... .......... .......... .......... .......... 
AG94 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG94 19wk .......... .......... .......... .E........ .......... .......... .......... H......... .......... .......... .......... .......... 
AG94 26wk .......... .......... .......... .E........ .......... .......... .......... H......... .......... .......... .......... .......... 
A086 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
A086 20wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AM20 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AM20 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..I ....... .......... 
17V  peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
17V  12wk .......... .......... .......... .......... .......... .......... .......... H......... .......... .......... .......... .......... 
17V  26wk ......S... .......... .......... .E........ .......... .......... .......... H......... .......... .......... ....R..... .......... 
DK40 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DK40 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DK40 26wk .......... .......... .......... .......... .......... ....I ..... .......... .......... .......... .......... .......... .......... 
AG46 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG46 16wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......K.. .......... .......... 
AG80 peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
AG80 18wk .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
DL6V peak .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 




























Figure 7 Consensus Env V1-V5 amino acid sequences generated by single genome amplification in longitudinal specimens from
untreated and PrEP breakthrough animals. Sequences are aligned with a reference SHIV162P3 isolate (GenBank accession number AF536757).
Amino acid changes in gp120 are shown for each animal.
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and Use Committee of the Centers for Disease Control and
Prevention approved these studies.
Viral RNA extraction and cDNA generation
Viral RNA was extracted from longitudinal plasma speci-
mens collected from macaques AG80, AG46, DK40, DL6V,
AM20, 17 V, AO86, AG94 and AI22 at peak viremia and
during 17 to 29 weeks of follow up using the QIAmp Viral
RNA Mini Kit (Qiagen) (Figure 1). Specimens were selected
based on detectable RNA in plasma by RT-PCR [7,8].
cDNA was generated by reverse transcription using primer
QZR2 (5′ ACA GCT CCT AGC GTC ACT GCT C 3′)
and Superscript III reverse transcriptase (RT) according to
the manufacturer’s instructions (Invitrogen, Carlsbad, Cali-
fornia). Briefly, 30 μl of plasma RNA were added to an RT
cocktail containing 1.5 μl of primer QZR2 (10 μM), 3 μldNTPs (10 mM), 3 μl DTT (100 mM), RNase OUT (120
units), and 600 units of Superscript III RT (Invitrogen) for a
total 60 μl reaction. Reverse transcription was done at 50°C
for 60 minutes and 55°C for 60 minutes. The mixture was
heat inactivated at 70°C for 15 minutes and then treated
with RNase H for 20 minutes at 37°C to remove the RNA
template.
Single genome amplification (SGA)
1.105 kb env sequences containing the V1-V5 region of
gp120 (nucleotide positions 348 to 1,453 relative to HIV-1
isolate SF162, GenBank accession number EU123924)
were generated by SGA. Briefly, serial dilutions of the RT-
generated cDNA were made in 96-well plates to identify
dilutions resulting in <30% of positive wells. Based on a
Poisson distribution, amplifications at this dilution repre-
sent sequences derived from a single cDNA copy [11]. PCR
Zheng et al. Retrovirology 2012, 9:40 Page 10 of 11
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dilution and a PCR cocktail containing primer QZF3 (5′
CCC ACA GAC CCT AAC CCA CAA GA 3′) and QZR2.
The mixture was incubated for 2 minutes at 94°C followed
by 40 cycles of 15 s at 94°C, 30s at 54°C, 90s at 68°C, and a
final extension of 15 minutes at 68°C. A 2-μl volume was
then used for a nested PCR reaction using primers QZF4
(5′ GCC ATG TGT AAA GTT AAC CCC ACT C 3′) and
QZR3 (5′ GCC TTG GTG GGT GCT ACT CCT A 3′)
and 45 cycles of 15 s at 94°C, 30 s at 54°C, 60 s at 68°C,
with a final extension of 15 minutes at 68°C. Nested-PCR
products were visualized using a pre-cast 96-well 1% agar-
ose gel system and the E-Editor software tool (Invitrogen,
Carlsbad, California). The number of positive wells was
computed to ensure an amplification rate lower than 30%.
Positive PCR products were then purified for subsequent
sequence analysis using the Quick PCR purification kit
(Qiagen).
Sequence analysis
Env sequences were obtained using an ABI3130xl auto-
mated sequencer with primers QZR3, QZR5 (5′ GGT CCC
CTC CTG AGG ATT GCT TA 3′), QZF7 (5′ CAG TCT
AGC AGA AGA AGG GGT AG 3′), QZF5 (5′ CAC AAG
CCT GTC CAA AGG TAT CC 3′, QZR6 (5′ GCT TTC
CCC GGT CCTATA GGTA 3′), and QZF8 (5′ TAC CTA
TAG GAC CGG GGA AAG C 3′). PCR conditions
included 25 cycles of 10s at 96°C and 10s at 55°C. The Vec-
tor NTI Advance program (version 11.5.0) was used to
analyze the data and to infer amino acid sequences.
Phylogenetic analysis was done using the MEGA (ver-
sion 5.0) software package. The Hasegawa, Kishino, and
Yano model with gamma distributed rates and a propor-
tion of invariable sites was inferred to be the best model
of nucleotide substitution for env sequences from each
individual animal, the SHIV inoculum, and all sequences
combined by using maximum likelihood (ML) best fit
analysis in the MEGA program. Nucleotide alignments
were prepared using Clustal W in MEGA. All indels
were manually removed from the alignments prior to
phylogenetic analysis. Phylogenetic trees were inferred
using neighbor joining (NJ) and ML methods and rooted
with the SHIV162P3 env consensus sequence. Viral diver-
sity was inferred by analysis of neighbor-joining trees
and the Highlighter tool available at http://www.hiv.lanl.
gov/content/sequence/HIGHLIGHT/highlighter.html.
The number of transmitted/founder variants that estab-
lished infection was determined by exploring the pattern
of env diversity at peak viremia. For this analysis, we
excluded hyper mutated sequences and gaps, and
assumed that variants with two or less unique nucleotide
changes arise from the same transmitted founder virus
[11]. Estimates of evolutionary divergence were done by
pairwise analysis of individual sequences and thetransmitted/founder virus using the maximum compos-
ite likelihood method in MEGA5, and results are
expressed as number of nucleotide substitutions per site
per year [27,28]. Mean nucleotide diversity and diver-
gence for PrEP breakthrough animals and controls were
compared by using a two-tailed t test (GraphPad Prism,
version 5.04). Tropism was evaluated using the geno2-
pheno co-receptor tool (Version 2.0) available at http://
coreceptor.bioinf.mpi-inf.mpg.de/index.php following the
recommendations from the European Consensus Group.
Potential N-linked glycosylation sites were analyzed
using the N- GlycoSite tool available at http://www.hiv.
lanl.gov/content/sequence/GLYCOSITE/glycosite.html.
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